{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.4","value":"1268"},{"groupId":"OG001","spread":"24.6","value":"1594"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG000","title":"Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg"},{"description":"Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG001","title":"Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Insufficient samples were taken in Cycle 2 and beyond to calculate PK parameters, therefore only Cycle 1 is reported. Includes data for all randomized participants for whom data were available.","reportingStatus":"POSTED","timeFrame":"Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1","title":"Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Total HuMax-TF (Conjugated and Non-conjugated)","type":"SECONDARY","unitOfMeasure":"h*µg/mL"}